ABBV 453
Alternative Names: ABBV-453Latest Information Update: 26 Aug 2025
At a glance
- Originator AbbVie
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Multiple myeloma
- Phase I Chronic lymphocytic leukaemia
Most Recent Events
- 23 Jul 2025 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater, Combination therapy) in Japan, Israel, USA (PO) (NCT06953960)
- 23 Jul 2025 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater, Monotherapy) in Japan, Israel, USA (PO) (NCT06953960)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in Australia (PO, Tablet)